Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 20;14(9):2061.
doi: 10.3390/cancers14092061.

Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC)

Taehee Lee  1   2 , Piper A Rawding  3   4 , Jiyoon Bu  3   4   5   6 , Sunghee Hyun  2 , Woosun Rou  7 , Hongjae Jeon  7 , Seokhyun Kim  8 , Byungseok Lee  8 , Luke J Kubiatowicz  3 , Dawon Kim  3   4 , Seungpyo Hong  3   4   9 , Hyuksoo Eun  8   10
Affiliations

Machine-Learning-Based Clinical Biomarker Using Cell-Free DNA for Hepatocellular Carcinoma (HCC)

Taehee Lee et al. Cancers (Basel). .

Abstract

(1) Background: Hepatocellular carcinoma (HCC) is one of the leading causes of cancer-related death worldwide. Although various serum enzymes have been utilized for the diagnosis and prognosis of HCC, the currently available biomarkers lack the sensitivity needed to detect HCC at early stages and accurately predict treatment responses. (2) Methods: We utilized our highly sensitive cell-free DNA (cfDNA) detection system, in combination with a machine learning algorithm, to provide a platform for improved diagnosis and prognosis of HCC. (3) Results: cfDNA, specifically alpha-fetoprotein (AFP) expression in captured cfDNA, demonstrated the highest accuracy for diagnosing malignancies among the serum/plasma biomarkers used in this study, including AFP, aspartate aminotransferase, alanine aminotransferase, albumin, alkaline phosphatase, and bilirubin. The diagnostic/prognostic capability of cfDNA was further improved by establishing a cfDNA score (cfDHCC), which integrated the total plasma cfDNA levels and cfAFP-DNA expression into a single score using machine learning algorithms. (4) Conclusion: The cfDHCC score demonstrated significantly improved accuracy in determining the pathological features of HCC and predicting patients' survival outcomes compared to the other biomarkers. The results presented herein reveal that our cfDNA capture/analysis platform is a promising approach to effectively utilize cfDNA as a biomarker for the diagnosis and prognosis of HCC.

Keywords: cell-free DNA (cfDNA); circulating tumor DNA (ctDNA); hepatocellular carcinoma (HCC); liquid biopsy; principal component analysis (PCA).

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Enhanced detection of cfDNA for its use as a biomarker for the diagnosis and prognosis of HCC. (A) A schematic diagram illustrating the cfDNA detection and analysis methods using PDA-SiO2 beads. (B) The copy numbers of plasma cfAFP-DNA isolated from human plasma samples using either PDA-SiO2 beads (black) or QIAamp DNA mini-kit (gray).
Figure 2
Figure 2
The diagnostic capability of cfDNA for detecting HCC patients from non-cancer (NC) cohorts: (A) the expression profiles of serum enzymes, plasma cfDNA, and cfAFP-DNA quantified from a total of 152 HCC patients and 97 non-cancer cohorts, which include 43 patients diagnosed with liver cirrhosis (LC), 24 patients diagnosed with alcoholic liver hepatitis (LA), and 30 healthy donors (HD). (B,C) ROC curves for diagnosing HCC from NC, LC, LA, and HDs using the expression profiles of serum enzymes, plasma cfDNA, and cfAFP-DNA. (D) Diagnostic performance of serum enzymes, plasma cfDNA, and cfAFP-DNA for detecting HCC patients.
Figure 3
Figure 3
The clinical performance of cfDNA for determining the pathological features of HCC tumors: (A) ROC curves for determining the UICC stages, existence of LVI, tumor size, and multifocality of a tumor. (B) Sensitivity, specificity, and accuracy of each biomarker for determining the UICC stages, existence of LVI, tumor size, and multifocality of a tumor.
Figure 4
Figure 4
The clinical performance of cfDNA for predicting the survival outcomes: Kaplan–Meier survival analysis for (A) recurrence, (B) marginal recurrence, (C) multifocal recurrence, and (D) overall survival of TACE-treated patients. Univariate Cox regression analysis of the serum and plasma biomarkers for (E) TACE-treated and (F) non-treated patients.
See this image and copyright information in PMC

References

    1. Llovet J.M., Kelley R.K., Villanueva A., Singal A.G., Pikarsky E., Roayaie S., Lencioni R., Koike K., Zucman-Rossi J., Finn R.S. Hepatocellular carcinoma. Nat. Rev. Dis. Primers. 2021;7:6. doi: 10.1038/s41572-020-00240-3. - DOI - PubMed
    1. Villanueva A. Hepatocellular carcinoma. N. Engl. J. Med. 2019;380:1450–1462. doi: 10.1056/NEJMra1713263. - DOI - PubMed
    1. Li L., Wang H. Heterogeneity of liver cancer and personalized therapy. Cancer Lett. 2016;379:191–197. doi: 10.1016/j.canlet.2015.07.018. - DOI - PubMed
    1. Akinyemiju T., Abera S., Ahmed M., Alam N., Alemayohu M.A., Allen C., Al-Raddadi R., Alvis-Guzman N., Amoako Y., Artaman A., et al. The Burden of Primary Liver Cancer and Underlying Etiologies from 1990 to 2015 at the Global, Regional, and National Level: Results from the Global Burden of Disease Study 2015. JAMA Oncol. 2017;3:1683–1691. - PMC - PubMed
    1. Ho D.W., Lo R.C., Chan L.K., Ng I.O. Molecular Pathogenesis of Hepatocellular Carcinoma. Liver Cancer. 2016;5:290–302. doi: 10.1159/000449340. - DOI - PMC - PubMed

LinkOut - more resources